NASDAQ:GILD - Gilead Sciences Stock Price, News, & Analysis

Get Started

$69.07 +0.42 (+0.61 %)

(As of 01/18/2019 01:56 PM ET)

Previous Close$68.65

Today's Range$68.51 - $69.57

52-Week Range$60.32 - $89.54

Volume393,020 shs

Average Volume7.83 million shs

Market Capitalization$87.50 billion

P/E Ratio8.07

Dividend Yield3.37%

Beta1.06

Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; and TARGET PharmaSolutions, Inc. The company was founded in 1987 and is headquartered in Foster City, California.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:GILD

Previous Symbol

CUSIP37555810

Webwww.gilead.com

Phone650-574-3000

Debt

Debt-to-Equity Ratio1.09

Current Ratio3.45

Quick Ratio3.37

Price-To-Earnings

Trailing P/E Ratio8.07

Forward P/E Ratio10.73

P/E Growth-2.34

Sales & Book Value

Annual Sales$26.11 billion

Price / Sales3.42

Cash Flow$9.8250 per share

Price / Cash Flow7.03

Book Value$15.69 per share

Price / Book4.40

Profitability

EPS (Most Recent Fiscal Year)$8.56

Net Income$4.63 billion

Net Margins7.12%

Return on Equity39.32%

Return on Assets12.73%

Miscellaneous

Employees10,000

Outstanding Shares1,293,620,000

Market Cap$87.50 billion

OptionableOptionable

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Thursday, October 25th. Investors of record on Friday, December 14th will be paid a dividend of $0.57 per share on Friday, December 28th. This represents a $2.28 annualized dividend and a yield of 3.28%. The ex-dividend date is Thursday, December 13th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) posted its quarterly earnings data on Thursday, October, 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. The biopharmaceutical company had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. During the same period in the previous year, the company earned $2.27 EPS. View Gilead Sciences' Earnings History.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Monday, February 4th 2019. View Earnings Estimates for Gilead Sciences.

How can I listen to Gilead Sciences' earnings call?

Gilead Sciences will be holding an earnings conference call on Monday, February 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

What price target have analysts set for GILD?

21 brokers have issued 12-month price targets for Gilead Sciences' stock. Their predictions range from $72.00 to $105.00. On average, they anticipate Gilead Sciences' share price to reach $88.3684 in the next twelve months. This suggests a possible upside of 27.3% from the stock's current price. View Analyst Price Targets for Gilead Sciences.

What is the consensus analysts' recommendation for Gilead Sciences?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 8 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

1. According to Zacks Investment Research, "Gilead’s HIV franchise maintains momentum, driven by the continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. The FDA approval of Biktarvy has further widened the portfolio. Biktarvy has also been approved in Europe. The launch of Yescarta is progressing well in the United States and the approval in Europe should boost sales. Meanwhile, Gilead is intending to foray into the nonalcoholic steatohepatitis (NASH) and inflammation markets with late-stage candidates, selonsertib and filgotinib, respectively. A tentative approval will diversify Gilead’s portfolio. The company has also made strategic collborations to boost its pipeline. Shares have outperformed the industry in the year so far. However, Gilead’s HCV franchise is under pressure due to competitive and pricing pressure. Also, the HIV franchise faces competition from the likes of Glaxo, among others." (12/31/2018)
2. Cantor Fitzgerald analysts commented, ": We are increasing our price target to $88 from $87 and reiterating our Overweight rating. Gilead beat top and bottom line consensus expectations as the Biktarvy launch remains strong in HIV. Our price target is higher by $1/share given revenue trends were slightly more robust than we projected. The company also increased its product revenue guidance to $20.8-21.3B from $20-21B. Product revenues were $5.45B and EPS were $1.84/share. Biktarvy beat expectations by ~$50M, as it reported revenues of $375M. GILD has also benefited from a generic Letairis not entering the market, and it doesn’t expect an entrant in 2018. We have updated our estimates for the quarter." (10/26/2018)
3. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)
4. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)

Has Gilead Sciences been receiving favorable news coverage?

Press coverage about GILD stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Gilead Sciences earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 14,461,682 shares, an increase of 15.0% from the December 14th total of 12,573,094 shares. Based on an average daily trading volume, of 9,743,024 shares, the short-interest ratio is presently 1.5 days. Currently, 1.1% of the shares of the stock are short sold. View Gilead Sciences' Current Options Chain.

Who are some of Gilead Sciences' key competitors?

Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO) and Denali Therapeutics (DNLI).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

Dr. John F. Milligan, CEO, Pres & Director (Age 57)
Ms. Robin L. Washington, CFO & Exec. VP (Age 55)
Mr. Kevin B. Young, Advisory (Age 60)
Dr. John G. McHutchison, Exec. VP of Research, Clinical R&D and Chief Scientific Officer
Sung Lee, VP of Investor Relations

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Confluence Investment Management LLC (0.09%), Gateway Investment Advisers LLC (0.06%), Nisa Investment Advisors LLC (0.04%), Personal Capital Advisors Corp (0.03%), Atalanta Sosnoff Capital LLC (0.03%) and Ferguson Wellman Capital Management Inc. (0.03%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Which institutional investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, Greylin Investment Mangement Inc., Nippon Life Global Investors Americas Inc., Edge Wealth Management LLC, Personal Capital Advisors Corp, Atalanta Sosnoff Capital LLC, Confluence Investment Management LLC and TB Alternative Assets Ltd.. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, John C Martin, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Which institutional investors are buying Gilead Sciences stock?

GILD stock was purchased by a variety of institutional investors in the last quarter, including QUANTRES ASSET MANAGEMENT Ltd, Ferguson Wellman Capital Management Inc., Virtu Financial LLC, DNB Asset Management AS, Bristol Advisors LLC, Town & Country Bank & Trust CO dba First Bankers Trust CO, Nisa Investment Advisors LLC and PFG Advisors. View Insider Buying and Selling for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $69.41.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $87.50 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is http://www.gilead.com.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)

Community Ranking:		3.5 out of 5 ( )
Outperform Votes:		1,978 (Vote Outperform)
Underperform Votes:		865 (Vote Underperform)
Total Votes:		2,843

MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/18/2019 by MarketBeat.com Staff

Featured Article: Why Net Income is Important to Investors